Company aims to keep patients out of hospital with a dual-mechanism rescue treatment to prevent vaso-occlusive crises 

CEO Torley continues to grow new-look Halozyme in wake of 2019 Phase III miss

Plus: SR One, RA Capital back $55M series D for ARS, and updates from Genuine, VectivBio-Comet, Amylyx, J&J, Levo, Gloria and Merck

Import, discount policies will have little effect in short-term